Scientists in Japan and Wisconsin used four genes to reprogram ordinary adult human being cells.

Advancing stem cell study and therapies while fully respecting the dignity of human being life The following statement was released by Cardinal Justin Rigali of Philadelphia, chairman of the Committee for Pro-Life Activities at the United States Conference of Catholic Bishops. Research published this week in the journals Cell and Research offer new hope for advancing stem cell analysis and therapies while completely respecting the dignity of human life.ARIAD has an collateral stake in Bellicum and is definitely eligible to receive milestones on regulatory and clinical progress and royalties on potential product sales. Bellicum is in charge of all manufacturing, regulatory and clinical activities and can hold the investigational new medication applications for these scheduled programs. Related StoriesScalable creation of gene therapy vectors: an interview with Frank UbagsImproved outcomes yielded from fresh ChIP-seq protocolJumping genes: a marker for early cancer diagnosis? An interview with Dr KazazianReGenX Biosciences to Develop ARGENT Gene Therapy Applications ReGenX and ARIAD Biosciences, LLC along with their academic colleagues at the University of Pennsylvania INFIRMARY, have got collaborated on the advancement of regulated in vivo production of therapeutic proteins for many years.